Showing results (2011-2020 of 2,088) with videos related to
Sort By:
Pageof 209
Plastic and Reconstructive Surgery|April 23, 2021
Evidence-Based Clinical Practice Guideline: Reconstruction after Skin Cancer ResectionAndrew Chen, John G Albertini, Jeremy S Bordeaux, et al.Journal of the American Academy of Dermatology|May 1, 2021
Evidence-based clinical practice guideline: Reconstruction after skin cancer resectionAndrew Chen, John G Albertini, Jeremy S Bordeaux, et al.Biorxiv : the Preprint Server for Biology|January 9, 2026
SNAP: Streamlined Nextflow Analysis Pipeline for Immunoprecipitation-Based Epigenomic Profiling of Circulating ChromatinZe Zhang, Paulo Da Silva Cordeiro, Surya B Chhetri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2023
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG OncologyAaron R Weiss, Yen-Lin Chen, Thomas J Scharschmidt, et al.MMWR. Morbidity and Mortality Weekly Report|May 19, 2017
Using Molecular Characterization to Support Investigations of Aquatic Facility-Associated Outbreaks of Cryptosporidiosis - Alabama, Arizona, and Ohio, 2016Michele C Hlavsa, Dawn M Roellig, Matthew H Seabolt, et al.Antiviral Research|November 22, 2024
Biological characterization of AB-343, a novel and potent SARS-CoV-2 Mpro inhibitor with pan-coronavirus activityKayleigh R McGovern-Gooch, Nagraj Mani, Dimitar Gotchev, et al.Journal of Medicinal Chemistry|February 11, 2026
Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin LymphomaDeborah S Mortensen, Hunter P Shunatona, Natalie Holmberg-Douglas, et al.Hepatology (Baltimore, Md.)|February 6, 2014
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosisLing Li, David Masica, Masaharu Ishida, et al.Journal of Medicinal Chemistry|February 1, 2024
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell MalignanciesDaniel W Robbins, Mark A Noviski, Ying Siow Tan, et al.Journal of the National Cancer Institute|October 15, 2010
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translationAndrew N Freedman, Leah B Sansbury, William D Figg, et al.Pageof 209